Pediatric vaccines in HIV-infected children

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 385-390

  Agosti, Jan M ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

HIV AIDS; Immunization; Pediatric; Vaccine

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HAEMOPHILUS INFLUENZAE TYPE B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFLUENZA; MORBIDITY; MORTALITY; PREVENTION AND CONTROL; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; VIRUS REPLICATION;

EID: 34547882822     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282cf4ccd     Document Type: Review

References (54)

1. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years: United States. MMWR 2007; 55:Q1-Q4. This reviews revised pediatric immunization schedules for the United States.
2. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet 2004; 4:510-518.
3. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull WHO 2003; 81:61-70.
4. Succi RC, Farhat CK. Vaccination in special situations. J Pediatr (Rio J) 2006; 82 (3 Suppl):S91-S100. This paper is a review of the safety and efficacy of vaccination in special situations such as immunosuppression, prematurity, pregnancy and postexposure.
5. Setse RS, Cutts F, Monze M, et al. HIV-1 infection as a risk factor for incomplete childhood immunization in Zambia. J Trop Pediatr 2006; 52:324-328. This is a nested case-control study of children hospitalized for measles to determine whether there is a link between HIV infection and incomplete immunization.
6. Serpe JN, Schmitz V, Lepage P. Vaccinations in HIV-infected children. Rev Med Liege 2005; 60:923-930.
7. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86:1082-1089.
8. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-1230.
9. Ramilo O, Hicks PJ, Borvak J, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996; 15c:197-203.
10. Fernandez-Ibieta M, Ramos-Amador JT, Aunon-Martin I. HIV-infected children vaccination coverage and safety in a Western European cohort: a retrospective study. Intl J STD AIDS 2007; 18:351-353. This describes a retrospective study of vaccine coverage, safety and adherence to recommendations of a cohort of HIV-positive children in Western Europe.
11. Sullivan PS, Hanson DL, Dworkin MS, et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000; 14:2781-2785.
12. Dunn D, Newell M, Packham C, et al. Routine vaccination and vaccine-preventable infections in children born to human immunodeficiency virusinfected mothers. Acta Paediatr 1998; 87:458-459.
13. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allerg Clin Immunol 2005; 116:698-703.
14. Ching N, Deville JG, Nielsen KA, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1 infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr 2007; 166:51-56. This describes a prospective study of immune response to a tetanus toxoid booster in perinatally acquired HIV-1-infected patients undergoing HAART who have received the primary tetanus immunization series.
15. Thaithumyanon P, Punnahitananda S, Praisuwanna P, et al. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai 2002; 85:277-282.
16. Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. J Adolesc Health 2001; 29:123-129.
17. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006; 24:3095-3099. This was a cross-sectional study of the prevalence of hepatitis B virus protective antibody in HIV-infected children after receiving HAART.
18. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902-2908.
19. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18:1161-1165.
20. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20:11-15. This is a review article.
21. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9. This was a laboratory-based surveillance study to document trends in pneumococcal disease in HIV-infected adults before and after the introduction of a pneumococcal vaccine.
22. Falco V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one-year follow-up study. Vaccine 2006; 24:2567-2574. This describes a follow-up study to determine the persistence of the response to pneumococcal vaccination after one year.
23. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-929. This study evaluated the safety and immunogenicity of PCV and PPV in HIV-positive children receiving HAART.
24. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol 2006; 118:1336-1341. This case-controlled study compared the immunological response to a pneumococcal vaccine in HIV-infected versus uninfected children.
25. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112 (1 Pt 1):66-73.
26. Russell FM, Mulholland EK. Recent advances in pneumococcal vaccination of children. Ann Trop Paediatr 2004; 24:283-294.
27. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and noninfected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-2457. This was a long-term follow-up study to determine the persistence of a response to a pneumococcal vaccine in HIV-infected versus noninfected children.
28. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24:6232-6239. This retrospective study evaluated the impact of the introduction of a Hib vaccine in a country with a high prevalence of HIV-infected children.
29. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21:315-321.
30. Chokephaibulkit K, Phongsamart W, Vanprapar N, et al. Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virusinfected Thai children older than 2 years old. Vaccine 2004; 22:2018-2022.
31. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-e644.
32. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-446.
33. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20:1124-1131.
34. Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006; 78:440-445. This study evaluated the safety and immunogenicity of a virosomal influenza vaccine in HIV-positive children receiving HAART.
35. Khanlou H, Sanchez S, Babaie M, et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunode-ficiency virus-positive patients. Arch Intern Med 2006; 166:1417.
36. Gouvea AV, De Moraes-Pinto MI, Ono E, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis 2005; 41:544-548.
37. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006; 13:81-86. This describes a retrospective study of the immune response to hepatitis A virus vaccine in HIV-infected patients.
38. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193:302-311. This study tested the safety and immunogenicity of hepatitis A virus vaccine in HIV-infected children receiving HAART.
39. Ragni MV, Lusher JM, Koerper MA, et al. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia 2000; 6:98-103.
40. Palefsky J. Human papillomavirus-related tumors in HIV. Curr Opin Oncol 2006; 18:463-468. This is a review article.
41. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-18. This describes a retrospective study of BCG vaccine-induced disease in both HIV-infected and uninfected children.
42. Revised BCG vaccination guidelines for infants at risk for HIV infection. Weekly Epidemiologic Record 2007; 82:193-196.
43. O'Brien LK, Ruff AJ, Louis MA, et al. Bacillus Calmette-Guerin complications in children born to HIV-1 infected women with a review of the literature. Pediatrics 1995; 95:414-418.
44. Marks K, Amitai Y, Engelhard D, et al. Mycobacterium bovis lymphadenitis complicating BCG immunization in an infant with symptomatic HIV-1 infection. Isr J Med Sci 1993; 29:381-382.
45. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immuno-compromised patients. JAMA 1992; 267:1237-1241.
46. Measles in HIV-infected children, United States. Morb Mortal Wkly Rep 1988; 37:183-186.
47. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. Morb Mortal Wkly Rep 1996; 45:603-606.
48. Al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titres after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14:149-151.
49. Aldeen T, Hay P, Davidson F, Lau R. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS 1998; 12:1719-1720.
50. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194:247-255. This study looked at the safety and immunogenicity of a live attenuated varicella virus vaccine in HIV-infected children with moderate or previously advanced immune suppression.
51. Armenian SH, Han JY, Dunaway TM, Church J. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J 2006; 25:368-370. This study tested the safety and immunogenicity of a live varicella virus vaccine in HIV-infected children.
52. Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006; 20:2321-2329. This study tested the safety and immunogenicity of a live-attenuated varicella vaccine in HIV-infected children after immune reconstitution.
53. Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet 2001; 358:550-555.
54. Sibally TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997; 16:1177-1179.